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ABSTRACT
Background: The cost of treating community-acquired pneumonia (CAP)
in China is a heavy economic burden for the society.
Objective: To investigate the costs of hospitalization of low-risk CAP
patients and how hospitalization costs can be reduced through proper
usage of hospital resources.
Methods: Two hundred thirty-six patients with low-risk CAP who were
hospitalized between January 2000 and December 2005 in a 1161-bed
tertiary care teaching hospital were included in a retrospective cohort
study. Their hospitalization costs and antibiotic therapy were analyzed.
General linear model was utilized to determine correlative variables asso-
ciated with total hospital costs.
Results: The median length of hospital stay was 12 days and the median
duration of intravenous (IV) antibiotic therapy was 10 days, they were
correlated signiﬁcantly (P = 0.000, r = 0.81). The median total hospital
cost was $556.50 (mean $705.60), of which 48.9% was for drugs,
21.9% for laboratory tests, 8.6% for radiology, 6.5% for medical staff,
6.3% for hospital beds, and 5.3% for examination. General linear
model analysis determined that duration of IV antibiotic therapy, Pneu-
monia Severity Index class, age, and initial empirical antibiotic therapy
failure were correlative factors of total hospital costs. Pathogens were
identiﬁed in 106 patients (44.9%), Mycoplasma pneumoniae was the
most common pathogen (19.9%), followed by Streptococcus pneumo-
niae (8.5%), and Haemophilus inﬂuenza (5.5%). The majority of
patients accepted initial empirical b-lactam (37.3%) or ﬂuoroquinolone
(30.9%) monotherapy, the empirical treatment failure rates were 20.5%
and 5.5%, respectively.
Conclusions: Efforts to reduce duration of IV antibiotic therapy will have
the most profound effect on reducing total hospital costs of low-risk CAP.
The atypical pathogens should be considered for initial empirical antibi-
otics in low-risk CAP therapy in China.
Keywords: antibiotic, community-acquired pneumonia, cost savings,
pneumonia severe index.
Introduction
Community-acquired pneumonia (CAP) is an acute respiratory
disease that may occur at any age. The cost of treating CAP is a
heavy economic burden for the society. The annual hospitalization
cost of CAP in adult was estimated to be over $8 billion in the
United States [1] and $136.85million in Spain [2]. The annual cost
of CAP was estimated to be NZ$63 million in New Zealand,
including direct medical costs of $29 million, direct nonmedical
costs of $1 million, and lost productivity of $33 million [3]. In
China, there is no available data about the annual cost of CAP, but
the Ministry of Health reported the mean hospitalization costs of
CAP was $575.3 in 2005, and it was much higher in tertiary
hospitalswhichwas $1137.3 [4]. In 1997, Fine et al. [5] developed
the Pneumonia Severity Index (PSI), which divided CAP into ﬁve
risk classes. The prediction rule identiﬁed three distinct risk classes
(I, II, and III) of patients whowere at sufﬁciently low risk for death
and other adverse medical outcomes who physicians could con-
sider for outpatient treatment, which could reduce the social
economic load. The PSI is now applied extensively worldwide. It
has been reported that it can be used in Chinese CAP patients and
has a good correlation with the disease severity criteria of the
Chinese guidelines for diagnosis and treatment of CAP [6]. But in
China, there were no strict indications of hospitalization in CAP
guidelines [7], and also no deﬁnite information in medical insur-
ance or care, so, some low-risk CAP patients were hospitalized,
including patients of treatment failure in clinic. In this study,
the clinical data and hospitalization costs of low-risk CAP pati-
ents were analyzed to determine the key factors in decreasing
hospitalization costs. To our knowledge, there is no previous study
about low-risk CAP in China.
Materials and Methods
Materials
We retrospectively analyzed CAP patients during the period
between 2000 and 2005 in Peking University Third Hospital,
which is a nonproﬁt, tertiary care teaching hospital with 1161
beds in Beijing, China. The diagnosis of pneumonia was made
according to the guidelines of CAP diagnosis and treatment made
by the Respiratory Society of the Chinese Medical Association
[7]. This included the presence of a new inﬁltration on chest
radiographs and at least one of the following: documentation of
a new cough with or without sputum production or exacerbation
of chronic respiratory diseases with purulent sputum production
with or without chest pain; documented fever (37.3°C); aus-
cultatory ﬁndings on pulmonary examination and/or evidence of
pulmonary consolidation; and white blood cells (WBC) count
>10 ¥ 109/L or leucopenia (WBC < 4 ¥ 109/L). Patients were clas-
siﬁed according to the PSI. Classes I, II, and III were considered
low-risk groups. Low-risk CAP patients who were at least 18
years of age were included in the study. Patients were excluded if
they had a positive titer of antibodies to the human immunode-
ﬁciency virus, had been hospitalized within 7 days before the
current admission, had been transferred from another acute care
hospital, had known or suspected tuberculosis or other infection
at baseline caused by viruses or fungi, or their medical records
were not included all variables of PSI score calculation. PSI class
IV and class V patients were also excluded.
Methods
This study was retrospective in design. The following clinical
data were collected: sex, age, source of payment for medical care
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(public medical care, national health insurance, self-pay medical
care), comorbid conditions (neoplastic disease, chronic obstruc-
tive pulmonary disease, cerebrovascular disease, diabetes, con-
gestive heart failure, cirrhosis or other chronic liver disease, or
chronic renal disease), PSI class, extent of lobar inﬁltration on
chest radiograph, length of hospital stay, duration of intravenous
(IV) antibiotic therapy, duration of IV antibiotic therapy after
body temperature (<37.3°C) and respiratory symptoms
(dyspnea, cough, and chest pain) improved, and whether initial
empirical antibiotic therapy failed. Clinical data were collected
from medical record after discharge. We also recorded total
hospital costs, including pharmacy, radiology, and laboratory
costs (including tests of blood, urine and stool, arterial blood gas,
and bacterial cultures), examination costs (including lung func-
tion tests, electrocardiogram, and ultrasound), medical staff fees
(including costs for physicians and nurses), bed or room fees, and
other costs such as nebulization and oxygen therapy. All patients
that our hospital costs database can supply were included in this
study. The factors inﬂuencing total hospital costs (total of phar-
macy, radiology, laboratory, examination, medical staff, and
other costs) were analyzed.
The deﬁnition of antibiotic therapy failure was no improve-
ment after 72 hours of therapy or improvement followed by
relapse [7]. All patients had at least one sputum culture (with
presence of <10 squamous epithelial cells and >25 polymorpho-
nuclear cells per ¥10 magniﬁcation ﬁeld) and a serum test for
IgM antibodies to Mycoplasma pneumoniae, Chlamydia pneu-
moniae, and Legionella pneumophila. Enzyme linked immun-
osorbent assay method was used in serum test. Sputum culture
and serum test for antibodies of atypical pathogens were done
within 48 hours of hospital admission.
Statistical Analysis
Data were extracted into a data ﬁle of SPSS (SPSS, Chicago, IL,
USA). The initial analysis separated the cohort into three groups
based on PSI class (classes I, II, and III) and costs were compared
between groups separated by outcomes of initial empirical antibi-
otic therapy. Total hospital costs were also compared among
groups separated by source of payment in each PSI class. Continu-
ous data were compared using one-way analysis of variance for
normally distributed data or nonparametric tests including the
Mann–Whitney U-test and the Kruskal–Wallis H-test for non-
normally distributed data. Chi-square tests were used for com-
parison of count data. Spearman correlation analysis was used to
determine correlation between duration of IV antibiotic therapy
and length of hospital stay. General linear model was utilized to
determine correlative variables of total hospital costs for the entire
cohort including sex, age, comorbid conditions, extent of lobar
inﬁltration on chest radiograph, initial empirical antibiotic
therapy failure, severity of illness, duration of IV antibiotic
therapy, and duration of IV antibiotic therapy after body tempera-
ture and respiratory symptoms improved, most of which were
supported from previous research. Intensive Care Unit (ICU)
admission and mortality also could inﬂuence total hospital costs
of CAP, but only low-risk CAP patients were included in the
current study, there was no ICU admission case and no patient
died. All correlative variables were entered into the model as
covariates at the same time.
A P-value <0.05 was considered signiﬁcant in all statistical
analyses. Normally distributed continuous data (e.g., age) are
expressed as mean  SD and non-normally distributed continu-
ous data (e.g., cost) are expressed as the median (25th to 75th
percentile). SPSS version 12 for Windows software (SPSS,
Chicago, IL) was used for statistical analysis.
Results
Demographic Data
In this study, we evaluated 236 low-risk CAP patients, including
130 patients (55.1%) in class I, 71 patients (30.1%) in class II,
and 35 patients (14.8%) in class III. In each year, from 2000 to
2005, there were 43, 68, 53, 19, 27, and 26 cases, respectively.
The age of patients was 41.0  19.8 years old, with 144 males
and 92 females. The age and percentage of patients who had
bilateral or multiple lobar inﬁltration increased with increasing
PSI risk class. Payments for medical care included national health
insurance in 91 (38.6%), public medical care in 106 (44.9%),
and self-pay medical care in 39 (16.5%) patients (Table 1).
Clinical Data
For all patients, the median length of hospital stay was 12 days,
median duration of IV antibiotic therapy was 10 days. Length of
hospital stay was signiﬁcantly correlated with duration of IV
antibiotic therapy (P = 0.000, r = 0.81). The median duration of
IV antibiotic therapy after body temperature recovered and res-
piratory symptoms improved was 7 days (Table 1).
Pathogens were identiﬁed in 106 patients (44.9%) with valid
serum samples and sputum cultures. M. pneumoniae was the
most common pathogen (47 cases, 19.9%), followed by Strep-
tococcus pneumoniae (20 cases, 8.5%), and Haemophilus inﬂu-
enza (13 cases, 5%). Pathogens of low-risk CAP were listed in
Table 2. Of the 54 patients with a bacterial pathogen, M. pneu-
moniae was identiﬁed in three cases whose sputum culture results
showed Klebsiella pneumoniae, Citrobacter freundii, and S.
pneumoniae, respectively.
Table 3 displays the list of antibiotic regimens utilized to
empirically treat low-risk CAP in these patients. The majority of
patients received b-lactam (88 cases, 37.3%) or ﬂuoroquinolone
(73 cases, 30.9%) monotherapy, or a combination of a ﬂuoro-
quinolone with a macrolide (42 cases, 17.8%). Eleven patients
(4.7%) received monotherapy with a macrolide and seven
patients (3.0%) received a b-lactam in combination with a mac-
rolide. The remaining 15 patients (6.3%) received alternative
regimens; but in all cases, a b-lactam, macrolide, or ﬂuoroqui-
nolone was utilized as at least one of the drugs in the regimen.
Antibiotics of b-lactams, macrolides, and ﬂuoroquinolones used
in initial empirical antibiotic therapy are listed in Table 4.
The initial empirical antibiotic therapy failed in 18 patients
who received a b-lactam as monotherapy and 4 patients who
received a ﬂuoroquinolone as monotherapy. Three of seven cases
receiving penicillin G as monotherapy failed, and two cases
changed regimens to monotherapy with other b-lactams and one
case changed to a ﬂuoroquinolone monotherapy. The empirical
therapy failed in 15 patients who received a b-lactam other than
penicillin G as monotherapy; they changed regimens which con-
tained at least one macrolide and ﬂuoroquinolone. Of the 73
patients who received monotherapy with a ﬂuoroquinolone, 4
cases failed and all changed regimens to monotherapy with
b-lactams other than penicillin G. The treatment outcome was
that 69.9% of patients were cured and 30.1% had remissions.
No patients died.
Costs of Hospitalization
Total and departmental costs are depicted in Table 5. From
2000 to 2005, the median total hospital costs for low-risk CAP
in our hospital was $556.50 (25th to 75th percentile, $359.10
to $889.00). The greatest percentage of total cost was allocated
to pharmacy costs, particularly antibiotics, at 48.9%, followed
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by laboratory costs (21.9%), radiology (8.6%), medical staff
(6.5%), hospital beds (6.3%), examination (5.3%), and others
(3.3%). The more severe the CAP, the more it cost to treat: PSI
class I, $500.60 (25th to 75th percentile, $318.90 to $732.70);
class II, $631.00 (25th to 75th percentile, $399.90 to
$1002.60); and class III, $908.60 (25th to 75th percentile,
$475.30 to $1471.60). The differences between PSI classes were
mainly because of pharmacy costs. Patients with successful
initial empirical antibiotic therapy had lower total hospital
costs than those who had failed initial therapy (median
$525.10 vs. $744.30, P = 0.041). There were no signiﬁcant dif-
ferences in total hospital costs among groups separated by
source of payment in each PSI class, P-value in PSI 1, PSI 2,
and PSI 3 were 0.206, 0.189, and 0.271, respectively.
Radiology costs for patients who were in PSI risk class II were
signiﬁcantly higher than other patients, which was mainly caused
by chest computed tomography (CT) scans. Patients in PSI class
II (0.65 times/patient) had more chest CT scans than those who
were in class I (0.35 times/patient) and class III (0.63 times/
patient; P = 0.002). The age of patients in class II was
47.5  18.6 years old, an age range at which lung cancer and
other diseases are so common that more attention is required and
chest CT scans were utilized more frequently for differential
diagnosis.
Independent variables included in the general linear model
predicting total hospital costs are shown in Table 6. Because
length of hospital stay was decided by duration of IV antibiotic
therapy (P = 0.000, r = 0.81), so the former could not be an
independent variable. Duration of IV antibiotic therapy, PSI
class, age, and initial empirical antibiotic therapy failure were
signiﬁcantly associated with higher total costs.
Discussion
In the current study, we analyzed hospitalization costs and anti-
biotic therapy for low-risk CAP patients admitted to a large
urban nonproﬁt university hospital from 2000 to 2005. The
duration of IV antibiotic therapy, PSI class, age, and initial
empirical antibiotic therapy failure were independently associ-
ated with total hospital costs.
Our ﬁnding that duration of IV antibiotic therapy were very
important in inﬂuencing length of hospital stay and total hospital
costs for CAP patients supports other studies [8–10]. IV antibi-
otic therapy is a very important mode of treatment for CAP
patients and has a quick response and good outcome. When the
Table 1 Demographic and clinical data for low-risk CAP patients and results for groups deﬁned by PSI class
Characteristics
All patients
(n = 236)
Groups separated by PSI class
P-value
Class I
(n = 130)
Class II
(n = 71)
Class III
(n = 35)
Age, year 41.0 19.8 29.6 9.2 47.5 18.6 70.2 14.6 0.000
Male gender 144 (61.0) 75 (57.7) 38 (53.5) 31 (88.6) 0.001
Sources of payment for medical care 0.661
Public medical care 106 (44.9) 64 (49.2) 29 (40.8) 13 (37.1)
National health insurance 91 (38.6) 47 (36.2) 29 (40.8) 15 (42.9)
Self-pay medical care 39 (16.5) 19 (14.6) 13 (18.4) 7 (20.0)
Comorbid conditions
Neoplasm 3 (1.3) 0 1 (1.4) 2 (5.7) 0.027
Cerebrovascular disease 3 (1.3) 0 1 (1.4) 2 (5.7) 0.027
COPD 3 (1.3) 0 0 3 (8.6) 0.000
Diabetes 2 (0.8) 1 (0.8) 1 (1.4) 0 0.75
Congestive heart failure 0 0 0 0
Renal disease 0 0 0 0
Liver disease 0 0 0 0
Bilateral or multiple lobars inﬁltration
on chest radiograph
65 (27.5) 29 (22.3) 17 (23.9) 19 (54.3) 0.001
Length of hospital stay, d 12.0 (9.0–18.0) 12.0 (9.0–16.0) 13.0 (10.0–18.0) 13.0 (8.0–22.0) 0.136
Duration of IV antibiotic therapy, d 10.0 (8.0–14.0) 10.0 (8.0–13.3) 10.0 (8.0–16.0) 11.0 (7.0–21.0) 0.602
Duration of IV antibiotic therapy
after body temperature and
respiratory symptoms
improved, d
7.0 (5.0–10.0) 7.0 (5.0–10.0) 7.0 (5.0–10.0) 7.0 (3.0–9.0) 0.547
Initial empirical antibiotic therapy failure 22 (9.3) 13 (10.0) 8 (11.3) 1 (2.9) 0.347
Admission year 0.914
2000 43 (18.2) 24 (18.5) 12 (16.9) 7 (20.0)
2001 68 (28.8) 40 (30.8) 17 (23.9) 11 (31.4)
2002 53 (22.5) 29 (22.3) 16 (22.5) 8 (22.9)
2003 19 (8.1) 8 (6.2) 7 (9.9) 4 (11.4)
2004 27 (11.4) 14 (10.8) 11 (15.5) 2 (5.7)
2005 26 (11.0) 15 (11.5) 8 (11.3) 3 (8.6)
Note:Age is presented as mean SD. Length of hospital stay, duration of IV antibiotic therapy, and duration of IV antibiotic therapy after body temperature and respiratory symptoms improved
are presented as median (25th to 75th percentile). Other data are presented as Number (%).
PSI, Pneumonia Severity Index; COPD, chronic obstructive pulmonary disease; IV, intravenous; CAP, community-acquired pneumonia.
Table 2 Pathogens identiﬁed in 236 low-risk CAP patients
Pathogens Number of cases Proportion (%)
Mycoplasma pneumoniae 47 19.9
Streptococcus pneumoniae 20 8.5
Haemophilus inﬂuenza 13 5.5
Acinetobacter 8 3.4
Chlamydia pneumoniae 5 2.1
Moraxella catarrhalis 3 1.3
Legionella pneumophila 3 1.3
Klebsiella pneumoniae 3 1.3
Enterobacter cloacae 2 0.8
Pseudomonas aeruginosa 2 0.8
Serratia marcescens 1 0.4
Staphylococcus epidermidis 1 0.4
Citrobacter freundii 1 0.4
CAP, community-acquired pneumonia.
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patients’ body temperature, however, has recovered and respira-
tory symptoms including dyspnea, cough, and chest pain have
improved, is it still essential to continue IV antibiotic therapy?
Would the prognosis be affected at this stage if we stopped IV
antibiotic therapy? Van der Eerden et al. [11] carried out a pro-
spective study in 180 adult CAP patients in The Netherlands.
They demonstrated that once body temperature was <38°C for
72 hours and respiratory symptoms including dyspnea, cough,
and chest pain had improved, switching to oral antibiotic therapy
was safe. In the same study, 174 patients (97%) were cured while
6 patients worsened after switching to oral antibiotic therapy. Of
these, ﬁve were cured after intensive therapy and one patient died
of non-CAP-related cardiac disease 2 weeks after admission.
There were two reported cases of failure out of a total of 104
low-risk CAP patients and the duration of IV antibiotic therapy
was 4 to 4.5 days. Fernandez Alvarez et al. [8] reported that the
mean duration of IV antibiotic therapy was 5.8 days in a study
including 125 hospitalized CAP patients. Although the duration
inﬂuenced mean hospital stay and cost, it did not add any evident
therapeutic beneﬁt. This research suggests that switching from IV
to oral therapy earlier in CAP patients is safe and effective,
especially in low-risk CAP patients. According to the Chinese
CAP guidelines, switching from IV to oral antibiotic therapy is
also recommended if the patient has apparently improved after
initial therapy for 48 to 72 hours. Therefore, shortening the
duration of IV antibiotic therapy appears feasible.
In our study, the median duration of IV antibiotic therapy
after the patient’s temperature and respiratory symptoms had
improved was 7 days, which is much longer than practices of
Europe and North America, and also longer than the recom-
mended duration according to Chinese CAP guidelines. If the
duration of IV antibiotic therapy in CAP patients is shortened,
the length of their hospital stay will also be shortened and hos-
pitalization costs will be lowered. Hospital stays can perhaps be
shortened to about 5 to 7 days, which is typical in developed
countries [5,12]. Shortening hospital stays would not necessarily
affect outcome. A study of 1188 hospitalized CAP patients dem-
onstrated that medical outcomes were similar in patients admit-
ted to the hospital with the shortest length of stay and those
admitted with longer mean lengths of stay [13].
There are distinct differences between China and developed
countries in the proportions of costs of hospitalizing CAP
patients. The median total hospital cost for low-risk CAP
patients in our study was $556.50 (mean $705.60), which is far
less than that of developed countries such as Singapore (mean
$2160) [12] and Germany (median of PSI risk classes I–III,
$987–$1465) [9]. In developed countries, hospital bed and
medical staff fees account for the largest percentage [9,14–16] of
total costs, while in our country, pharmacy costs account for the
largest percentage of total hospital costs for CAP treatment
[4,17], which was 48.9% in our study.
Pharmacy costs was nearly 50% of total costs in our hospital,
it is much higher than that of developed countries, which was
only 4.6% to 20.8% [9,14–16,18,19]. The antibiotics used in
our hospital were almost the same with developed countries, and
the prices were not higher than those of developed countries. The
high pharmacy costs proportion was caused partly by inappro-
priate long duration of IV antibiotic therapy; it is expected to be
decreased by switching from IV to oral antibiotic therapy earlier
[20]. At the same time, costs for beds and medical staff in our
hospital were much less and proportionally lower than those of
developed countries, so the pharmacy costs proportion appeared
even higher.
Noticeably, the instruments for examination and laboratory
reagents used in our hospital in recent years were almost as
advanced as those used in the United States, but patients in China
paid far less. Laboratory and examination costs were still pro-
Table 3 Antibiotic regimens and duration of IV antibiotic therapy
Empirical antibiotic regimens
All patients Patients with empirical antibiotic therapy failure
Number (%)
(n = 236)
Duration of IV antibiotic
therapy (d)
Number
(failure rate)
Duration of IV antibioti
therapy (d)
b-Lactam monotherapy 88 (37.3) 11.0 (8.0–15.8) 18 (20.5) 13.0 (10.0–17.8)
Penicillin G monotherapy 7 (3.0) 11.0 (10.0–17.0) 3 (42.9%) 17.0 (11.0–20.0)
Other b-lactam monotherapy 81 (34.3) 11.0 (8.0–15.0) 15 (18.5%) 13.0 (10.0–17.0)
Fluoroquinolone monotherapy 73 (30.9) 10.0 (7.0–12.0) 4 (5.5%) 10.0 (7.5–11.0)
Macrolide plus ﬂuoroquinolone 42 (17.8) 11.0 (8.8–16.0) 0
Macrolide monotherapy 11 (4.7) 8.0 (2.0–12.0) 0
b-Lactam plus macrolide 7 (3.0) 13.0 (10.0–17.0) 0
b-Lactam plus ﬂuoroquinolone 4 (1.7) 9.5 (6.3–21.0) 0
Fluoroquinolone plus clindamycin 4 (1.7) 12.0 (8.25–22.5) 0
b-Lactam plus clindamycin 3 (1.3) 13.0 (5.0–13.0) 0
b-Lactam plus aminoglycoside 2 (0.8) 20.0 (8.0–32.0) 0
b-Lactam plus macrolide plus ﬂuoroquinolone 2 (0.8) 19.0 (10.0–28.0) 0
Note: Duration of IV antibiotic therapy is shown as median (25th to 75th percentile).
IV, intravenous.
Table 4 Antibiotics of b-lactam, macrolide, and ﬂuroquinolones used in
initial empirical antibiotic therapy
Antibiotics Number of cases Proportions (%)
Beta-lactams 106 44.9
Cefuroxime 46 19.5
Ceftriaxone 13 5.5
Penicillin G 10 4.2
Ertapenem 10 4.2
Cefutaxime 7 3.0
Ceftazidime 5 2.1
Cefepime 3 1.3
Amoxicillin-clavulanate 3 1.3
Piperacillin 2 0.8
Ampicillin-sulbactam 2 0.8
Cefoperazone-sulbactam 2 0.8
Cefalexin 2 0.8
Imipenem-cilastatin sodium 1 0.4
Macrolides 69 29.2
Azithromycin 44 18.6
Erythromycin 21 8.9
Roxithromycin 4 1.7
Fluroquinolones 125 53.0
Levoﬂoxacin 98 41.5
Gatiﬂoxacin 23 9.7
Oﬂoxacin 4 1.7
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portionally high in our hospital mainly because of low costs for
beds and medical service. As a developing country, the total
hospital costs of CAP treatment should be lower than that of
developed countries, but the proportional costs of medical
service and beds are expected to be high.
Bertran et al. [21] reported that the clinical effectiveness of
the ﬁrst antibiotic used was the main variable in determining the
ﬁnal average cost per patient treated. For patients with lower
respiratory tract infections, the therapeutic option with a better
cost-effectiveness ratio must be chosen to minimize the risk of
therapeutic failure after ﬁrst line therapy. In the current study,
initial empirical antibiotic therapy failure also was an important
factor that could increase total hospital costs for CAP patients.
The total hospital cost of patients with initial empirical therapy
success were signiﬁcantly lower than that of patients with failed
initial empirical therapy (median $525.10 vs. median $744.30,
P = 0.041); there were no signiﬁcant differences of the initial
empirical therapy failure rate among groups separated by PSI
class (P = 0.347). Thus, increasing the success rate of initial
empirical antibiotic therapy is important for decreasing total
hospital costs.
According to the Chinese CAP guidelines [7] published in
1999, the pathogens of CAP in hospitalized patients were
mainly bacteria, such as S. pneumoniae and H. inﬂuenzae. In
addition, in China, S. pneumoniae has a 73.9% resistance rate
to erythromycin [22] and a 75.4% resistance rate to azithro-
mycin [23], so macrolides were not recommended to be ﬁrst
antibiotics in CAP treatment. In our study, only 11 cases were
treated by macrolides monotherapy because they were diag-
nosed as possible atypical pneumonia by physician. Therefore,
the initial empirical antibiotic regimen to CAP patients in this
study was in accordance with the guidelines in China. But in
recent years, M. pneumoniae was found more and more impor-
tant in CAP, including in low-risk patients. M. pneumoniae was
the common pathogen of low-risk CAP in our current study,
which is consistent with other studies [23,24]. Liu et al. [23]
reported the results of a multi-center study of urban CAP
pathogens that identiﬁed M. pneumoniae in 20.7% of patients,
especially in those who were no more than 50 years old (about
30%) and those who had no coexisting illness (24.1%). At the
same time, Mycoplasma was found to be the most common
pathogen coexisting with bacteria. In our current study, empiri-
cal b-lactam monotherapy, which has no effect on Mycoplasma,
had a higher failure rate (20.5%) than other regimens contain-
ing at least one macrolide or ﬂuoroquinolone, which both work
well to treat Mycoplasma infection. New CAP guidelines pub-
lished in 2006 has paid more attention to atypical pathogens in
CAP empirical antibiotics therapy [25].
Therefore, the initial empirical antibiotic therapy for low-risk
CAP should cover atypical pathogens (mainly M. pneumoniae)
and S. pneumoniae and H. inﬂuenza, which are still the top two
CAP bacteria [23–26]. New ﬂuoroquinolones such as levoﬂoxa-
cin and moxiﬂoxacin are efﬁcient not only for atypical pathogens
but also for common CAP bacteria. They had high success rates
as empirical monotherapy inour study (only 4 cases failed among
73 patients). Based on the current study and recent studies about
etiology of CAP [23,24], we suggest the empirical antibiotic
regime of a b-lactam plus macrolide or new ﬂuroquinolones
monotherapy which can cover not only atypical pathogens but
also common bacteria for low-risk CAP. Fluoroquinolones,
however, have been used so widely both in human beings and
animals in China that there is a high rate of resistance in many
bacteria, and there is cross-resistance to new ﬂuoroquinolones
[27], so we should pay attention to avoid high resistance to new
ﬂuoroquinolones.Ta
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There were limitations in our study. First, it was a single-
center study that just reﬂected the state of tertiary hospitals in
Beijing and can not represent the state of secondary level and
primary level hospitals. Second, it was a retrospective analysis
and lacked randomization. Third, 12 low-risk CAP patients who
had incomplete clinical data were excluded, which may lead to
sample-related bias. Lastly, patients who were treated in clinics
were not included in this study, so the pathogen limited in hos-
pitalized low-risk CAP patients, and antibiotic therapy before
admission would inﬂuence the result of sputum culture.
In conclusion, duration of IV antibiotic therapy, PSI class,
age, and initial empirical antibiotic therapy failure were signiﬁ-
cantly correlated with total hospital costs for low-risk CAP
patients admitted into our tertiary urban hospital. The length of
hospital stay can be shortened by switching earlier from IV to
oral antibiotic therapy. Focused efforts to reduce duration of IV
antibiotic therapy should have the most profound effect on
reducing total hospital costs. The atypical pathogens should be
considered for initial empirical antibiotics in low-risk CAP
therapy in China.
Source of ﬁnancial support: None.
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